Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies.
Journal: Cancer research communications
Published: February 10, 2023
Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer.
Journal: Nature cancer
Published: April 05, 2022
The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity.
Journal: Nature communications
Published: October 23, 2020
Epstein-Barr Virus-Encoded Latent Membrane Protein 1 and B-Cell Growth Transformation Induce Lipogenesis through Fatty Acid Synthase.
Journal: Journal of virology
Published: September 23, 2020
Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1.
Journal: PLoS pathogens
Published: June 18, 2018
PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type.
Journal: Journal of virology
Published: April 30, 2018
MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.
Journal: Blood advances
Published: February 27, 2017
PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
Journal: Virology
Published: December 19, 2016
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
Journal: Molecular cancer research : MCR
Published: December 16, 2016
Last Updated: 09/26/2026